2022-11-15T18:32:48-06:00 2021-12-31 814234542 BPM LLP 4200 BOHANNON DRIVE SUITE 250 MENLO PARK CA 940251021 990 2021-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 JAMES PALAZZOLO CEO 8558660505 2022-11-15 1 JAMES PALAZZOLO 999009999 CAROLYN R AMSTER P00189994 6508556800 2022-11-15 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z JAMES PALAZZOLO 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 56142324 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER AND COVID-19 RESEARCH AND TREATMENT. 13 12 82 0 0 0 12701393 33562189 28181045 22548772 86104 31363 -1884 0 40966658 56142324 35000 25791 0 0 4039299 10422634 0 0 321508 19481659 33307137 23555958 43755562 17410700 12386762 46710842 64443428 28501320 33840706 18209522 30602722 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 39584786 22236632 I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER. 734688 BREAST CANCER TRAILS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES. 568402 COLLABORATION WITH THE ATHENA BREAST HEALTH NETWORK - THE ATHENA BREAST HEALTH NETWORK ("ATHENA") IS A COLLABORATION OF THE FIVE UNIVERSITY OF CALIFORNIA MEDICAL CENTERS AND SANFORD HEALTH TO DRIVE INNOVATION IN BREAST CANCER PREVENTION, SCREENING AND TREATMENT. A LARGE-SCALE DEMONSTRATION PROJECT, ATHENA INTEGRATES CLINICAL CARE AND RESEARCH TO DRIVE INNOVATION IN PREVENTION, SCREENING, TREATMENT AND MANAGEMENT OF BREAST CANCER. THIS PROJECT WILL IMPROVE SURVIVAL AND REDUCE SUFFERING FROM BREAST CANCER BY ACCELERATING THE TIME BETWEEN RESEARCH DISCOVERIES AND INNOVATIVE PATIENT TREATMENTS. MAJOR INITIATIVES INCLUDE RISK ASSESSMENT AND EVALUATION, RADIOLOGY HARMONIZATION, PATHOLOGY HARMONIZATION, AND IMPROVING SURVIVORSHIP CARE. 1342599 25791 312140 1342599 25791 312140 42230475 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 53 0 1 82 1 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X X THE ORGANIZATION 8558660505 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 LAURA ESSERMAN DIRECTOR, COFOUNDER 20.00 X X 0 0 0 JEFFREY PFEFFER DIRECTOR, COFOUNDER 0.50 X X 0 0 0 DAVE MANDELKERN CHAIRMAN 12.00 X X 120488 0 0 ANNA BARKER DIRECTOR 0.50 X 0 0 0 LUCAS DEBREED DIRECTOR 0.50 X 0 0 0 SUSAN FOLEY TREASURER 0.50 X X 0 0 0 MICHELE MARKUS DIRECTOR 0.50 X 0 0 0 ROBERT PATTERSON DIRECTOR 0.50 X 0 0 0 ROBYN LAWRIE RUTLEDGE DIRECTOR 0.50 X 0 0 0 GREGORY C SIMON DIRECTOR 0.50 X 0 0 0 MARK SIMON DIRECTOR 0.50 X 0 0 0 N MARCUS THYGESON DIRECTOR 0.50 X 0 0 0 LAMBERT VAN DER WALDE DIRECTOR 0.50 X 0 0 0 JAMES PALAZZOLO CEO 40.00 X 449962 0 35544 PAUL HENDERSON SENIOR DIRECTOR OF COLLABO 40.00 X 208405 0 41891 KARYN DIGIORGIO COO 40.00 X 263026 0 32149 TRACEY L HEATHER DIRECTOR OF DEVELOPMENT 40.00 X 216016 0 43388 RUIXIO LU SENIOR SOFTWARE ENGINEER 40.00 X 273636 0 46315 KATHRYN J WATSON-FEINER DIRECTOR OF FINANCE 40.00 X 283349 0 8599 1814882 0 207886 36 0 1 0 NOHA LIM 13503 HUNTING HILL WAY NORTH POTOMAC MD 20878 CONSULTING SERVICE 2701630 NCOMPASS RECRUITING SERVICES 3247 WARREN LANE EL DORADO HILLS CA 95762 RECRUITING 849844 OWL BROOK ASSOCIATES LLC PO BOX 5218 HANOVER NH 03755 CLINICAL DATA WORKFLOW, DESIGN, & TESTIN 729875 SURESH GADAMSETTY 1501 DECOTO ROAD APT 118 UNION CITY CA 94587 SOFTWARE DEVELOPMENT AND TECHNICAL ASSIS 213940 STEFFANIE GOODMAN 2030 FELL STREET 2 SAN FRANCISCO CA 94117 CONSULTING SERVICE 177900 11 32977715 584474 23400 33562189 CLINICAL TRIAL CONTRACTS 541511 22236632 22236632 CONSULTING AND RESEARCH CONTRACTS 541511 312140 312140 22548772 31363 31363 56142324 22548772 0 31363 25791 25791 605994 576267 22621 7106 7921362 6934476 792711 194175 193734 170637 18524 4573 1138755 1002996 108880 26879 562789 495695 53810 13284 92525 88391 3118 1016 319638 305355 10771 3512 4288909 4106248 137064 45597 5826653 5798589 13780 14284 290953 273383 13392 4178 17924 16686 1238 66083 64374 1290 419 88780 67928 20852 RESEARCH SITES 15223948 15223948 PROGRAM MANAGEMENT 4520577 4519887 690 RESEACH 2507660 2507660 OTHER PROGRAM EXPENSES 68047 56724 4838 6485 -4560 -4560 43755562 42230475 1203579 321508 4496261 3320860 18411525 44752067 9708493 1775471 12302273 4913529 93609 2884 228131 1802060 319581 109079 73511 210502 1394394 7666055 2645 0 46710842 64443428 17442360 25408456 11058960 8432250 28501320 33840706 X 15697161 28731090 2512361 1871632 18209522 30602722 46710842 64443428 X 12386762 42535 -36097 X 0 0 0 X 3033157 1203352 1876103 12652517 33562189 52327318 3033157 1203352 1876103 12652517 33562189 52327318 1548641 50778677 121682 87600 31363 240645 52567963 83471985 0.96600 0.82420 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 319581 109079 210502 210502 PART XI, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSES PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSES X 0 0 0 0 0 0 0 1 0 JAMES PALAZZOLO CEO 349962 0 100000 0 0 0 0 0 35544 0 485506 0 0 0 RUIXIO LU SENIOR SOFTWARE ENGINEER 272000 0 1636 0 0 0 10801 0 35514 0 319951 0 0 0 KARYN DIGIORGIO COO 249987 0 13039 0 0 0 6556 0 25593 0 295175 0 0 0 KATHRYN J WATSON-FEINER DIRECTOR OF FINANCE 269117 0 14232 0 0 0 8599 0 0 0 291948 0 0 0 TRACEY L HEATHER DIRECTOR OF DEVELOPMENT 205036 0 10980 0 0 0 8766 0 34622 0 259404 0 0 0 PAUL HENDERSON SENIOR DIRECTOR OF COLLABO 197400 0 11005 0 0 0 7269 0 34622 0 250296 0 0 0 PART I, LINE 3 BONUSES ARE APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHNICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST OR THROUGH THE QUANTUM LEAP HEALTHCARE COLLABORATIVE WEBSITE, AS WELL AS TO ANYONE WHO REQUESTS THEM IN WRITING. THEY ARE ALSO AVAILABLE FOR INSPECTION AT THE QLHC OFFICE DURING NORMAL BUSINESS HOURS. FORM 990, PART XI, LINE 9: RETURNED UNSOLD ACTION ITEMS -36,097.